Skip to main content
Erschienen in: BMC Infectious Diseases 1/2017

Open Access 01.12.2017 | Research article

Clinical features of pulmonary cryptococcosis among patients with different levels of peripheral blood CD4+ T lymphocyte counts

verfasst von: Qian He, Yuan Ding, Wei Zhou, Hongxing Li, Ming Zhang, Yi Shi, Xin Su

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2017

Abstract

Background

The clinical manifestation of pulmonary cryptococcosis varies notably between immunocompromised and immunocompetent patients. To better understand pulmonary cryptococcosis, we compared the clinical features of pulmonary cryptococcosis patients with or without decreased peripheral blood CD4+ T cell counts.

Methods

We retrospectively reviewed the medical records of 80 patients with cryptococcosis who had been treated in Jingling Hospital from January 2011 to January 2016. According to the normal range of peripheral blood CD4 + T-lymphocyte counts in our population, we chose CD4 = 378/μL as a cut-off value.

Results

The proportion of fever in the patients with decreased CD4+ T cells was higher than that of the patients with a normal amount of CD4+ T cells (86.7% vs 28.6%, P < 0.001). The incidence of clinical symptoms, such as cough (60.6% vs 64.7%, P = 0.729), chest pain (9.1% vs 26.5%, P = 0.064), and dyspnea (27.3% vs 23.5%, P = 0.725) showed no difference between patients with low CD4+ T cell counts and those with normal CD4+ T cell counts. The number of asymptomatic patients in the CD4+ T cell normal group was higher than that in the decreased CD4+ T cell group (17.1% vs 0%, P = 0.005). Nodules, masses, and halo signs were more common in the CD4+ T cell normal patients than in the low-CD4+ T cell patients (79.4% vs 54.5%, P = 0.03). The opposite trend was observed for cavitations (14.7% vs 51.5%, P = 0.001). The other CT findings, including pulmonary consolidation (P = 0.205), and pleural effusion (P = 0.641), did not differ significantly between the two groups.

Conclusions

CD4+ T lymphocytes have a significant impact on the clinical and radiological characteristics of pulmonary cryptococcosis. The patients with normal CD4+ T cell counts were found to have less fever and more nodule-like radiographic findings.

Trial registration

2011NJKY-023-01. Registered on January 10, 2011.
Abkürzungen
ATG
rabbit anti-thymocyte globulin
CSF
cerebrospinal fluid
CT
computed tomography
CTD
connective tissue disease
SOT
solid organ transplant

Background

Cryptococcosis is a fungal infection that may cause serious pulmonary lesions and meningitis. In 2009, Benjamin et al. found that approximately two thirds of patients died within three months after an infection was diagnosed [1]. Additional predisposing factors included underlying solid organ transplantation [2], aggressive cancer treatment, use of immunosuppressants or glucocorticoids, connective tissue diseases, or conditions that may damage immune function [3]. At the same time, an increasing numbers of reports have found that cryptococcosis may happen in immunocompetent patients [46]. According to those reports, clinical manifestation can differ considerably between immunocompromised and immunocompetent patients.
CD4+ T lymphocytes play a pivotal role in protecting the body from Cryptococcus infection. The CD4+ T-cell immune response may be developed through Cryptococcus mannosylation [7], which can recruit macrophages and granulocytes to the lungs in pulmonary cryptococcosis [8]. In a cryptococcal meningitis mouse model, CD4+ T cells were also found to mediate fungal clearance [8]. A clinical study found that the use of rabbit anti-thymocyte globulin (ATG) or alemtuzumab is associated with increased cumulative incidence of cryptococcosis in organ transplant recipients. These medicines can induce substantial decreases in CD4 + T cells [8]. CD4 + T-lymphocyte deficiency is one of a main predisposing factors of cryptococcosis, whereby a CD4+ T-cell count below 100 cells/μl and detectable serum cryptococcal antigen portend high risk for HIV-associated cryptococcosis [9, 10]. Cryptococcosis has also been observed in idiopathic CD4 lymphocytopenia [11, 12]. In our previous study, we determined that low peripheral blood CD4+ T cells may cause more dissemination [13]. In previous studies, patient grouping based on immune status was mainly based on underlying diseases and suffered from a lack of objective criteria [6, 14]. In this study, we analyzed the clinical features, chest images, and prognosis of pulmonary cryptococcosis in patients with different peripheral blood CD4+ T lymphocyte counts.

Methods

This retrospective study was carried out in Nanjing Jinling Hospital. Records of patients with definite or probable cryptococcosis who were admitted during a five-year period (from January 2011–January 2016) were examined. Patient demographics, underlying disease, clinical manifestations, computed tomography (CT), diagnosis, treatment, and prognosis were analyzed. The relevant follow-up data were obtained through regular clinical interviews or via telephone calls. The last follow-up information was collected on May 30, 2016.

Diagnosis of cryptococcosis

A definite diagnosis of cryptococcosis was made if the patient met at least one of the following conditions: (1) positive histopathology from tissue samples acquired by open lung biopsy, percutaneous lung biopsy, transbronchial biopsy, or skin biopsy; or (2) positive culture of Cryptococcus from cerebrospinal fluid (CSF) or blood. Probable diagnostic criteria were: patients with a positive cryptococcal capsular polysaccharide antigen test in CSF or serum and patients who presented typical clinical manifestations [15, 16]. Exclusion criterion: the patient had no CD4+ T-lymphocyte count when diagnosed with cryptococcosis.
We used flow cytometry to determine the CD4 + T-lymphocyte count in patients’ peripheral blood. The normal range of CD4 + T-lymphocyte counts varied depending on the population. According to the standard used in our laboratory, the normal CD4 + T-cell value was 691/μL ± 273/μL (95% reference range:378/μL–1085/μL). For this reason, we chose CD4+ T cells of less than 378/μL as a cut-off value. The APACHE II score was used to evaluate the disease severity, which was determined according to the patient’s condition prior to antifungal therapy.

Statistical analysis

The chi-square test was used for inter-group comparisons with categorical variables. Continuous variables were analyzed by Independent Samples t test. All of the data were analyzed with SPSS version 20.0 for Windows. P values < 0.05 were considered to be statistically significant.

Results

Patient demographics

We examined the records of 80 patients who were diagnosed with cryptococcosis from January 2011 to January 2016. Among these cases, the CD4+ T-lymphocyte counts were equal to or less than 378/μL in 45 patients and the others patients were higher than 378/μL. There were no significant differences between the two groups with respect to gender (P>0.05, Table 1). The underlying diseases of the two groups are summarized in Table 1. In the normal CD4+ T cell group, 53.3% (24/45) of patients had used immunosuppressants or corticosteroids. Likewise, 28.6% (10/35) of patients in the low CD4+ T cell group had used immunosuppressants or corticosteroids (Table 1).
Table 1
Demographic features and underlying diseases of 80 patients with cryptococcosis
 
CD4 ≤ 378/μL
N = 45 (%)
CD4 > 378/μL
N = 35 (%)
P-value
Male (N)
28 (62.2)
25 (71.4)
0.39
Age (years)
 Mean ± SD
40.3 ± 14.0
44.2 ± 13.2
0.210
 Range
16–78
18–71
 
Underlying disease
 AIDS
14 (31.1)
0
 
 SOT
9 (20)
3 (8.6)
 
 Autoimmune disease
11 (24.4)
2 (5.7)
 
 Renal disease
3 (6.7)
4 (11.4)
 
 Blood disease
1 (2.2)
1 (2.9)
 
 Diabetes mellitus
1 (2.2)
4 (11.4)
 
 Malignant tumor
2 (4.4)
0
 
 Other diseases
1 (2.2)
4 (11.4)
 
 No diseases
3 (6.7)
17 (48.6)
<0.001
Medication history
 Corticosteroids
24 (53.3)
10 (28.6)
0.026
 immunosuppressants
18 (40)
6 (17.1)
0.027
Exposure history
3 (6.7)
3 (8.6)
 
AIDS acquired immune deficiency syndrome, SOT solid organ transplant, Exposure history: close contact with animal excreta, such as pigeon droppings or other natural materials contaminated by fungi

Clinical features

Six patients in the normal CD4+ T cell group (6/35,17.1%) had no symptoms but they were admitted due to the detection of radiographic shadows during chest X-rays at a check-up. All of the participants in the low CD4+ T cell group had symptoms, and the most common symptoms were fever (39/45,86.7%), which was only seen in 10 patients in the normal CD4+ T cell group (10/35,28.6%, P < 0.001). There was no difference between the two groups in the incidence of clinical symptoms, such as cough (20/33 vs 22/34, P = 0.729), chest pain (3/33 vs 9/34, P = 0.064), and dyspnea (9/33 vs 8/34, P = 0.725). Differences between the two groups in the prevalence of headache, dizziness (P = 1.0) and meningeal irritation (P = 0.624) did not reach statistical significance. Concerning the APACHE II score, there was a significant difference between the two groups (P < 0.001) (Table 2).
Table 2
Clinical characteristics of 80 patients with cryptococcosis
 
CD4 ≤ 378/μL
N = 45 (%)
CD4 > 378/μL
N = 35 (%)
P value
Clinical characteristics
 Asymptomatic
0
6 (17.1)
0.005
 Fever
39 (86.7)
10 (28.6)
<0.001
Pulmonary symptoms
33 (73.3)
34 (97.1)
 
 Cough and expectoration
20 (60.6)a
22 (64.7)a
0.729
 Chest pain
3 (9.1)a
9 (26.5)a
0.064
 Dyspnea
9 (27.3)a
8 (23.5)a
0.725
Neurological symptoms
34 (75.6)
4 (11.4)
 
 Headache, dizzy
30 (88.2)b
4 (100)b
1.000
 Meningeal irritation
19 (55.9)b
3 (75)b
0.624
APACHE II score
9.1 ± 3.7
3.2 ± 4.7
<0.001
aThe proportion of patients with pulmonary involvement
bThe proportion of patients with brain involvement

Chest radiography

The CT scan data were collected from 67 patients, including 33 patients in the low CD4+ T cell group and 34 patients in the normal CD4+ T cell group. The characteristics of the images are given in Table 3. Of the 67 patients, most patients’ pulmonary lesions were within a single lobe. There was no statistically significant difference between the low CD4+ T cell group and the normal CD4+ T cell group when we compared the proportion of single lobe lesions(19/33 vs 18/34,P = 0.703). The distribution of lesions was predominately peripheral and adjacent to the pleura. The difference between the two groups did not reach statistical significance (30/34 vs 28/33, P = 0.962). The difference in proportion of pulmonary consolidation between the two groups was not significantly different (P = 0.205). Nodules/masses were more common in the CD4+ T cell normal group than that in the CD4+ T cell decreased ones.(27/34 vs 18/33, P = 0.03). Cavitations within the nodules/masses were more frequent in the CD4+ T cell decreased patients (17/33 vs 5/34, P = 0.001). The halo sign was significantly less frequent in the low CD4+ T cell patients than in the normal CD4+ T cell patients (6/33 vs 15/34, P = 0.022). Pleural effusion was rare in both of the groups (4/33 vs 2/34, P = 0.641) (Table 3).
Table 3
Radiological patterns of pulmonary abnormalities of CT scans
 
CD4 ≤ 378/μL
N = 33 (%)
CD4 > 378/μL
N = 34 (%)
P value
Distribution of lesions
 Solitary (single lung)
4 (12.1)
7 (20.6)
0.173
 Multiple (single lung)
15 (45.5)
11 (32.4)
0.271
 Multiple (bilateral lung)
14 (42.4)
16 (47.1)
0.703
 Adjacent to the pleura
28 (84.8)
30 (88.2)
0.962
Lesion characterization
 Nodule or mass
18 (54.5)
27 (79.4)
0.030
 Consolidations
10 (30.3)
15 (44.1)
0.205
 Mixed alterations
4 (12.1)
8 (23.5)
0.223
 Cavitations
17 (51.5)
5 (14.7)
0.001
 Halo sign
6 (18.2)
15 (44.1)
0.022
Pleural effusion
4 (12.1)
2 (5.9)
0.641

Treatment

Treatments included surgery, medication, and a combination of both. In the CD4+ T cell decreased group, all of the patients received antifungal therapy. In the normal CD4+ T cell group, two patients were treated with surgery alone, two had surgery and postsurgical medication, and 31 received medication alone.

Prognosis

The outcome was 90-day all-cause mortality. Mortality attributable to cryptococcosis was also determined. In the low CD4+ T cell group, 13 patients died, most of whom (11 patients) had serious cryptococcal meningitis. In the normal CD4+ T cell group, only two patients died of cryptococcal meningitis. During the follow-up, no relapse was observed in any of the four cases that received pulmonary surgical treatment. The majority of the patients who completed drug therapy in both groups are still alive and the lesions had shrunk significantly and did not subsequently grow (Table 4).
Table 4
Treatment and prognosis of 80 patients with cryptococcosis
 
CD4 ≤ 378/μL
N = 45 (%)
CD4 > 378/μL
N = 35 (%)
P value
Prognosis
 Survival
32 (71.1)
33 (94.3)
0.008
 Death
13 (28.9)
2 (5.7)
 

Discussion

Cell immunity, especially the CD4 + T-cell-mediated immune response, plays important roles in protection against Cryptococcus infection. Currently, the related data of CD4 + T cells concerning cryptococcosis were from small sample studies or case reports [11]. Articles related to the assessment of the severity of cryptococcosis and prognosis through CD4 + T cells are rare. For this reason, the purpose of this study was to retrospectively characterize the clinical features, radiological characteristics, and outcomes of patients with different CD4+ T-lymphocyte counts.
In general, males are more frequently infected than females [17]. In the current study, the disease was also predominant in males. In addition to HIV and organ transplants, connective tissue disease (CTD), chronic leukemia, tumors, and diabetes have also been shown to predispose patients to cryptococcosis [18]. According to the classification method used in previous studies, patients with no underlying disease or diabetes mellitus patients were classified as the immunocompetent group. However, in the current study, we found that some of the patients had lower CD4 + T-lymphocyte counts. While these participants shared many of the same basic diseases as transplant patients, they tended to have lower CD4 + T-lymphocyte counts, but there were still some patients with normal CD4 + T counts. For this reason, the CD4 + T-lymphocyte counts may objectively represent the patient’s immune status.
In addition to host immune factors, cryptococcosis can also be related to environmental exposure to contaminated airspace, including close contact with animal excreta, especially pigeon droppings or other natural materials contaminated by fungi [19]. In this study, only six patients had a history of direct exposure to pigeon droppings, while in other studies, nearly half of the cryptococcosis patients had direct or potential environmental exposure history in south China [20]. This may be because the patients’ exposure history records are not comprehensive. These data suggest that we should pay more attention to the details of potential exposure risk factors of fungal spores.
In recent studies, nearly one third of immunocompetent patients with cryptococcosis were asymptomatic [21]. In the current study, 17.1% of patients with normal CD4+ T cell counts and cryptococcosis were asymptomatic, and their disease was detected incidentally during routine chest radiography or follow-up for other diseases. This situation can also be manifested in other common diseases of the respiratory system, including lung cancer. In this way, pulmonary cryptococcosis is likely to be misdiagnosed.
The most common symptom of cryptococcosis in the current study was fever (61.3%). Some studies have shown that HIV-infected patients are more likely to be febrile than non-immunosuppressed patients [22]. This study produced similar findings. The proportion of fever in patients with low CD4+ T cell counts (86.7%) was higher than that in patients with normal CD4+ T cell levels (28.6%). We speculate that low CD4+ T cell patients have a greater Cryptococcus burden and more brain involvement, which may cause more systemic inflammation and consequently fever symptoms. The other symptoms, such as coughing and expectoration, headache and dizziness, chest pain, and dyspnea showed no significant differences between the two groups.
In the previous study, APACHE II scores of immunosuppressed patients were similar to those of HIV patients and also markedly higher than non-immunosuppressed patients (P = 0.002) [22]. In the current study, the APACHE II scores were significantly lower in the patients with low CD4+ T cells than in the CD4+ T cell normal patients (P < 0.001). According to the description above (infection site/clinical feature/APACHE II scores), the results showed that the CD4+ T-lymphocyte counts can effectively assess the disease severity of cryptococcosis patients.
The radiographic features of pulmonary cryptococcosis were varied. Previous studies have focused on radiographic findings in immunocompetent cohorts or immunocompromised individuals based on underlying disease [14, 23]. The most common finding of chest imaging of pulmonary cryptococcosis in the current study was nodules or masses (54.5% in CD4+ T cell decreased patients and 79.4% in CD4+ T cell normal patients), but the results showed that the nodules/masses were significantly more common in the patients with normal CD4+ T cell counts than in those with low CD4+ T cell counts. This differs from findings reported by Xie et al., who indicated that there was no statistically significant difference between immunocompetent and immunocompromised patients with respect to underlying disease [14]. Chang et al. found that cavitation within nodules/masses was more common in immunocompromised patients than that in immunocompetent ones (P = 0.05), which is similar to the current findings [6]. The halo sign was significantly less frequent in the patients with low CD4+ T cell counts than that in the patients with normal CD4+ T cell counts (18.2% vs 44.1%, P = 0.022). However, in another study, Xie et al. reported that there was not a significant difference between the two groups according to underlying diseases [14]. Other less common findings, such as pleural effusion, which was also rare in our study [14](12.1% in the patients with low CD4+ T cell counts and 5.9% in the patients with normal CD4+ T cell counts, P = 0.64).
If cryptococcal spores reach the lung, they are predisposed to deposition in the peripheral subpleural alveoli [24]. In the current study, lesions were peripherally located in 86.6% of the 67 patients (84.8% in the patients with low CD4+ T cell counts and 88.2% in the patients with normal CD4+ T cell counts, P = 0.962), which is similar to the findings of the studies published by Lacomis et al. [25] and Fox et al. [26] (66.2% and 80%, respectively). We also found the lesions to be distributed mainly across single lung. This performance may be associated with the manner in which the spores were inhaled.
Pathologically, most of the nodules and masses were characterized by a granulomatous reaction. The response was composed of macrophages with epithelioid features, multinucleated giant cells, lymphocytes, and langhans type [27]. A Japanese study found that complete granuloma formed with central fibrosis in immunocompetent groups [28]. In the current study, this pathologic reaction was prone to primarily occur in individuals with normal CD4+ T cell counts because these patients had normal immune function. Conversely, the Japanese study also showed that, in a group of AIDS patients, the number of macrophages, lymphocytes, and giant cells was low. Many organisms were scattered in the lungs. We speculate that intact granuloma cannot form and numerous Cryptococcus reproduce in immunocompromised patients, which destroy the structure of the lung and cause the dissemination of pathogens. In our CT images, cavitation within nodules/masses was common in the low CD4+ T cell group. The halo sign was used to describe the hemorrhagic nodules in the CT image, which is fairly common in patients with invasive aspergillosis. A previous study showed that the pathology of the halo sign indicates granulomatous inflammation [14, 29]. In this way, these imaging findings are more likely to appear in the CD4+ T cell normal patients.
Mortality was markedly higher in the patients with low CD4+ T cell counts (28.9%) than in the patients with normal CD4+ T cell counts (5.7%). It may be that the former were likely to suffer from disseminated cryptococcosis. In addition to the site of infection, other reasons were analyzed as follows: First, the lack of effective means of screening in primary hospitals may cause delayed or incorrect diagnoses. Second, in consideration of renal toxicity, we only used azole antifungal agents rather than amphotericin B in the kidney transplant patients in the early period of each case. At the same time, the lack of the amphotericin B liposome is another important reason.
In the current study, patients with low CD4 + T-lymphocyte counts showed more severe clinical symptoms and CT manifestations than those with normal counts. Their Apache II scores were higher than those of the normal CD4 + T lymphocyte patients. In this way, the CD4 + T count can indicate the severity of cryptococcosis and facilitate the estimation of prognosis.
The present study has some limitations. First, it was a retrospective study and examined a small number of patients with cryptococcosis. Second, the abovementioned CD4 + T count indicated a point of the disease and lack of a dynamic evolution process. According to the current study, we should routinely check CD4 + T cell counts and perform a chest CT scan when the patient is highly suspected to have cryptococcosis.

Conclusions

CD4+ T lymphocytes have a significant impact on the clinical and radiological characteristics of pulmonary cryptococcosis. The patients with normal CD4+ T cell counts were found to have less fever symptoms and more nodule-like radiographic changes.

Acknowledgements

We thank LetPub for its linguistic assistance during the preparation of this manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81330035), Medical and Health Research Foundation of Nanjing Military Command (No. 12MA082), and National Key Technology Support Program from Ministry of Science and Technology (2015BAI12B11).

Availability of data and materials

Data supporting the conclusions are included within this article. Raw data will be made available upon requests made to Qian He.
The Ethics Committee of the Jinling Hospital approved the research protocol. Informed consent was obtained from all of the patients.
No patient identifiable material is presented.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30.CrossRefPubMed Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30.CrossRefPubMed
2.
Zurück zum Zitat Henao-Martínez AF, Beckham JD. Cryptococcosis in solid organ transplant recipients. Curr Opin Infect Dis. 2015;28(4):300–7.CrossRefPubMed Henao-Martínez AF, Beckham JD. Cryptococcosis in solid organ transplant recipients. Curr Opin Infect Dis. 2015;28(4):300–7.CrossRefPubMed
3.
Zurück zum Zitat Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54.CrossRefPubMed Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54.CrossRefPubMed
4.
Zurück zum Zitat Piyavisetpat N, Chaowanapanja P. Radiographic manifestations of pulmonary cryptococcosis. J Med Assoc Thail. 2005;88(11):1674–9. Piyavisetpat N, Chaowanapanja P. Radiographic manifestations of pulmonary cryptococcosis. J Med Assoc Thail. 2005;88(11):1674–9.
5.
Zurück zum Zitat Pulmonary cryptococcoma a rare and challenging diagnosis in immunocompetent patients . Pulmonary cryptococcoma a rare and challenging diagnosis in immunocompetent patients .
6.
Zurück zum Zitat Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest. 2006;129(2):333–40.CrossRefPubMed Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest. 2006;129(2):333–40.CrossRefPubMed
7.
Zurück zum Zitat Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus Neoformans mannoprotein. J Infect Dis. 2007;196(5):796–800.CrossRefPubMed Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus Neoformans mannoprotein. J Infect Dis. 2007;196(5):796–800.CrossRefPubMed
8.
Zurück zum Zitat Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol. 1994;55(1):35–42.PubMed Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol. 1994;55(1):35–42.PubMed
10.
Zurück zum Zitat Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856–62.CrossRefPubMedPubMedCentral Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856–62.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore). 2007;86(2):78–92.CrossRef Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore). 2007;86(2):78–92.CrossRef
12.
Zurück zum Zitat Régent A, Autran B, Carcelain G, et al. Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine (Baltimore). 2014;93(2):61–72.CrossRef Régent A, Autran B, Carcelain G, et al. Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine (Baltimore). 2014;93(2):61–72.CrossRef
13.
Zurück zum Zitat Ding Y, Li P, He Q, Wei H, Wu T, Xia D, Tan M, Shi Y, Su X. The CD4(+) T-lymphocyte count is an important predictor for the prognosis of cryptococcosis. Eur J Clin Microbiol Infect Dis. 2017;36:897–904.CrossRefPubMed Ding Y, Li P, He Q, Wei H, Wu T, Xia D, Tan M, Shi Y, Su X. The CD4(+) T-lymphocyte count is an important predictor for the prognosis of cryptococcosis. Eur J Clin Microbiol Infect Dis. 2017;36:897–904.CrossRefPubMed
14.
Zurück zum Zitat Xie LX, Chen YS, Liu SY, Shi YX. Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol. 2015;56(4):447–53.CrossRefPubMed Xie LX, Chen YS, Liu SY, Shi YX. Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol. 2015;56(4):447–53.CrossRefPubMed
15.
Zurück zum Zitat Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest. 2003;124:2143–7.CrossRefPubMed Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest. 2003;124:2143–7.CrossRefPubMed
16.
Zurück zum Zitat Zhu LP, JQ W, Xu B, XT O, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med Mycol. 2010;48(4):570–9.CrossRefPubMed Zhu LP, JQ W, Xu B, XT O, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med Mycol. 2010;48(4):570–9.CrossRefPubMed
17.
Zurück zum Zitat Differential Survival for Men and Wo Source PLoS One SO 2015 10 6 e0123119[PMIDT26107253] . Differential Survival for Men and Wo Source PLoS One SO 2015 10 6 e0123119[PMIDT26107253] .
18.
Zurück zum Zitat Chopra S, Capoor MR, Mallik R, et al. Pulmonary Cryptococcosis in HIV- sero-negative patients: case series from India. Mycoses. 2015;58(5):288–93.CrossRefPubMed Chopra S, Capoor MR, Mallik R, et al. Pulmonary Cryptococcosis in HIV- sero-negative patients: case series from India. Mycoses. 2015;58(5):288–93.CrossRefPubMed
19.
Zurück zum Zitat Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet Biol. 2015;78:7–15.CrossRefPubMed Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet Biol. 2015;78:7–15.CrossRefPubMed
20.
Zurück zum Zitat Xie X, Xu B, Yu C, et al. Clinical analysis of pulmonary cryptococcosis in non-HIV patients in south China. Int J Clin Exp Med. 2015;8(3):3114–9.PubMedPubMedCentral Xie X, Xu B, Yu C, et al. Clinical analysis of pulmonary cryptococcosis in non-HIV patients in south China. Int J Clin Exp Med. 2015;8(3):3114–9.PubMedPubMedCentral
21.
Zurück zum Zitat Kishi K, Homma S, Kurosaki A, Kohno T, Motoi N, Yoshimura K. Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. Respir Med. 2006;100(5):807–12.CrossRefPubMed Kishi K, Homma S, Kurosaki A, Kohno T, Motoi N, Yoshimura K. Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. Respir Med. 2006;100(5):807–12.CrossRefPubMed
22.
Zurück zum Zitat Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Inf Secur. 2010;61(5):419–26. Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Inf Secur. 2010;61(5):419–26.
23.
Zurück zum Zitat Hu Z, Xu C, Wei H, et al. Solitary cavitary pulmonary nodule may be a common CT finding in AIDS-associated pulmonary cryptococcosis. Scand J Infect Dis. 2013;45(5):378–89.CrossRefPubMed Hu Z, Xu C, Wei H, et al. Solitary cavitary pulmonary nodule may be a common CT finding in AIDS-associated pulmonary cryptococcosis. Scand J Infect Dis. 2013;45(5):378–89.CrossRefPubMed
24.
25.
Zurück zum Zitat Lacomis JM, Costello P, Vilchez R, Kusne S. The radiology of pulmonary cryptococcosis in a tertiary medical center. J Thorac Imaging. 2001;16(3):139–48.CrossRefPubMed Lacomis JM, Costello P, Vilchez R, Kusne S. The radiology of pulmonary cryptococcosis in a tertiary medical center. J Thorac Imaging. 2001;16(3):139–48.CrossRefPubMed
26.
Zurück zum Zitat Fox DL, Müller NL. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients. AJR Am J Roentgenol. 2005;185(3):622–6.CrossRefPubMed Fox DL, Müller NL. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients. AJR Am J Roentgenol. 2005;185(3):622–6.CrossRefPubMed
27.
Zurück zum Zitat Shibuya K, Hirata A, Omuta J, et al. Granuloma and cryptococcosis. J Infect Chemother. 2005;11(3):115–22.CrossRefPubMed Shibuya K, Hirata A, Omuta J, et al. Granuloma and cryptococcosis. J Infect Chemother. 2005;11(3):115–22.CrossRefPubMed
28.
Zurück zum Zitat Yanagawa N, Sakai F, Takemura T, et al. Pulmonary cryptococcosis in rheumatoid arthritis (RA) patients: comparison of imaging characteristics among RA, acquired immunodeficiency syndrome, and immunocompetent patients. Eur J Radiol. 2013;82(11):2035–42.CrossRefPubMed Yanagawa N, Sakai F, Takemura T, et al. Pulmonary cryptococcosis in rheumatoid arthritis (RA) patients: comparison of imaging characteristics among RA, acquired immunodeficiency syndrome, and immunocompetent patients. Eur J Radiol. 2013;82(11):2035–42.CrossRefPubMed
29.
Zurück zum Zitat Zinck SE, Leung AN, Frost M, Berry GJ, Müller NL. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr. 2002;26(3):330–4.CrossRefPubMed Zinck SE, Leung AN, Frost M, Berry GJ, Müller NL. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr. 2002;26(3):330–4.CrossRefPubMed
Metadaten
Titel
Clinical features of pulmonary cryptococcosis among patients with different levels of peripheral blood CD4+ T lymphocyte counts
verfasst von
Qian He
Yuan Ding
Wei Zhou
Hongxing Li
Ming Zhang
Yi Shi
Xin Su
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2017
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2865-z

Weitere Artikel der Ausgabe 1/2017

BMC Infectious Diseases 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.